FogPharma

Mathai Mammen, M.D., Ph.D. caught up with BiotechTV's Brad Loncar at #Benchtalk to discuss the latest advances in our Helicon discovery platform and our lead clinical candidate FOG-001, a first-in-class beta-catenin:TCF inhibitor for the treatment of colorectal cancer and other solid tumors. Our platform seamlessly integrates AI and experimental technologies to navigate the astronomical number of potential Helicon configurations (more than 10^60) and find solutions to problems previously considered impossible to solve. Mathai also discussed the high bar of what constitutes a useful innovation that we in the biopharma industry need to hold.    See a preview below, & watch the full interview here: https://lnkd.in/gtdwz7KM #AI #DataScience #MachineLearning

We’re developing medicines to address the most pressing needs in cancer treatment today. But we know that individuals and families face many kinds of hardship after a cancer diagnosis that extend far beyond the hospital or clinic: disruption to daily life, feelings of isolation, and logistical and financial burdens from treatment and care.       For that reason, we felt honored recently to volunteer at the American Cancer Society Hope Lodge in Boston, a place that offers cancer patients and their caregivers a free ‘home away from home’ during their treatment. Due to fortuitous scheduling, one patient and her caregiver happened to be a relative of one of own employees, and allowed our team to support each other in our personal as well as work lives. The Hope Lodge provides more than just lodging; it fosters a supportive environment where patients can focus on healing, surrounded by the strength and hope of others facing similar journeys.       Thank you to the Hope Lodge team for the opportunity to serve with you and to help support cancer patients and their loved ones.       #HopeLodge #Volunteering #Cancer

On this #WorldCancerResearchDay, we’re proud to be one of the organizations transforming cutting-edge science into real medicines for patients with cancer. In 2022, nearly 10 million people died from cancer, making it one the leading causes of death globally. The worldwide lifetime risk of developing cancer is approximately 25% according to recent global estimates. This means that about 1 in 4 people will develop cancer at some point during their lifetime. In addition, the global economic impact cost of cancer is estimated at $1.16 trillion annually in healthcare costs, productivity losses, and mortality.       Our Helicon therapeutics are uniquely able to address some of the most universal, but difficult-to-drug, mechanisms driving cancer progression, including protein-protein interactions. FOG-001, our investigational candidate in a Phase 1/2 clinical trial for patients with solid tumors, inhibits the protein-protein interaction between β-catenin and TCF which is known to drive many cancers, including colorectal cancer. In pursuit of our mission to make medicines that will transform the lives of patients with devastating diseases, we are advancing a number of other Helicon therapeutics we hope will have life-changing impact for people with cancer. 🌍🔬     #CancerResearch #Biotech 

Here’s a surprising question: What does a giraffe have in common with drug development? Fog CEO Mathai Mammen, M.D., Ph.D. explored the connection in his presentation at #SciFooCamp, a gathering of innovators at Cambridge University this summer.       For over 200 years, diseases have been named by where in the body they appeared and other descriptions based on our five senses. Now, as science has begun to unravel the molecular mechanisms of some diseases, it’s clear that our existing disease labels often do not reflect the mechanism of a condition; disease names often cluster different molecular mechanisms together, and sometimes separate conditions that are mechanistically the same.     Why should we care?  Descriptions of disease that turn out not to be mechanistically homogeneous make it awfully difficult to expect a medicine that works by some mechanism to impact that whole disease.  And conversely, it makes it wasteful to develop medicines for different diseases that should be considered the same as they are caused by the same mechanism.  This conundrum is the basis of a movement called Precision Medicine – but so far this movement has not moved much beyond oncology, virology and certain childhood genetic diseases.  The rest of medicine awaits.      It's imperative, Mathai argues, to embrace a new way of thinking in #drugdiscovery and #drugdevelopment, categorizing and diagnosing diseases by their mechanism rather than anatomically, so we can create medicines that work for patients.   Watch the full presentation here: https://bit.ly/3Y8raZV    #Biotechnology #PrecisionMedicine

We were honored to recently host Barbara Weber, MD for the first of a new series of fireside chats at our offices spotlighting women executives in life sciences. Dr. Weber is a member of our Board of Directors who has a long and accomplished career in oncology drug development, including in her current role as president and CEO of Tango Therapeutics. In our lively and intimate discussion, Dr. Weber shared reflections on her professional journey, along with her learnings on leadership, mentorship, and growth across all stages of a career. It was a thought-provoking and inspiring event — sincere thanks, Dr. Weber, for generously sharing your time and insights. #Learning #FiresideChat #Oncology

We’re excited to welcome Karthik Sriram as our new Vice President, Financial Planning & Analysis.   With over 16 years of experience in pharma and biotech, Karthik brings extensive expertise in financial management, strategic planning, and business development. Karthik’s addition to our leadership team will help drive our continued progress to fundamentally change treatment possibilities for cancer and other diseases with critical need.   We’re glad to have you on the team, Karthik! #Biotech #Finance

We’re proud to recognize a number of talented team members who have recently received promotions.   Having a growth mindset is a key part of our identity at Fog. It drives us to be constantly curious, to creatively knock down barriers standing in our way, and to pursue things others might dismiss as impossible.   Mitchell Larios, Sophie Minniti, Clare Fraser, Erica Visness, Kerry Marasa Cadigan, Warren (Ed) Dorsch, Diwakar Pattabiraman, Olena Tokareva, PhD, and Amanda Garofalo, congratulations on your new role! We’re looking forward to continuing to grow together.  #TeamPromotions 

Our CEO Mathai Mammen, M.D., Ph.D. will be speaking at the upcoming #BioCenturyGrandRounds as part of an illustrious panel of biopharma, regulatory and clinical experts entitled “Data for purpose: go big, go deep, or go long?” The panel will discuss how researchers are prioritizing data collection and application in the setting of real-world logistical constraints, and what the future of improved data collection looks like.      Data science is core to our #drugdiscovery and development work at Fog. We’re applying physics-based computational methods and artificial intelligence to aid in the invention of Helicons, a powerful peptide modality capable of “drugging” what has thus far has been completely intractable.  The larger biopharmaceutical ecosystem is starting to pay close attention to the multiple important problems encountered en route to a medicine that can be addressed by emerging technologies.    Learn more about Grand Rounds and explore the full agenda here: https://lnkd.in/gakuvuEn   #DataScience #Biotech 

We’d like to introduce the newest member of #TeamFogPharma: Amrith Bennet, our new Associate Vice President, Toxicology. Amrith’s 20+ years of experience in drug discovery and development will deepen the talent of our already-exceptional R&D group. In his role, Amrith will oversee the design and execution of nonclinical safety programs, supporting the development of safe and effective new medicines from discovery through to market authorization.  This new position for Fog will enable us to continue to grow our pipeline and leverage our Helicon technology, in oncology and beyond, to make extraordinary medicines. Welcome to the team, Amrith!  #Biotech #DrugDiscovery 

FogPharma CEO Mathai Mammen, M.D., Ph.D. spoke recently with MIT Sloan CDO about the powerful convergence of the parallel revolutions in the medical sciences and data science (AI), its significance for those aspiring to work in the biopharma industry, and its role in driving the next wave of therapeutic breakthroughs.     Our discovery engine has been custom-built to create a powerful drug modality that allows us to pursue medicines not currently possible anywhere else. We have assembled a top-tier team that relentlessly invents what we need and aims to create unique and effective medicines.       Read the full article here: https://bit.ly/46ZI3IT        #Biotech #MachineLearning #AI